iTeos Therapeutics Inc. (ITOS): Price and Financial Metrics


iTeos Therapeutics Inc. (ITOS): $28.20

0.74 (+2.69%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ITOS Stock Price Chart Interactive Chart >

Price chart for ITOS

ITOS Price/Volume Stats

Current price $28.20 52-week high $47.61
Prev. close $27.46 52-week low $17.43
Day low $27.25 Volume 119,300
Day high $28.52 Avg. volume 327,782
50-day MA $26.25 Dividend yield N/A
200-day MA $28.94 Market Cap 992.92M

iTeos Therapeutics Inc. (ITOS) Company Bio


iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. It offers immuno-oncology therapeutics for patients. The company was founded by Michel Detheux in April 2012 and is headquartered in Cambridge, MA.


ITOS Latest News Stream


Event/Time News Detail
Loading, please wait...

ITOS Latest Social Stream


Loading social stream, please wait...

View Full ITOS Social Stream

Latest ITOS News From Around the Web

Below are the latest news stories about iTeos Therapeutics Inc that investors may wish to consider to help them evaluate ITOS as an investment opportunity.

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Is About To Turn The Corner

iTeos Therapeutics, Inc. ( NASDAQ:ITOS ) is possibly approaching a major achievement in its business, so we would like...

Yahoo | September 2, 2021

iTeos Therapeutics to Participate in Upcoming September Investor Conferences

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immune-oncology therapeutics for patients, today announced that company management will participate in five upcoming virtual investor conferences in September:

Intrado Digital Media | September 1, 2021

iTeos Therapeutics Inc.: iTeos Therapeutics to Participate in Upcoming September Investor Conferences

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and developm

FinanzNachrichten | September 1, 2021

iTeos Reports Second Quarter 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Aug. 12, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today reported financial results for the second quarter ended June 30, 2021 and provided recent business highlights.

Intrado Digital Media | August 12, 2021

iTeos Therapeutics Inc.: iTeos Reports Second Quarter 2021 Financial Results and Provides Business Update

Announced co-development and co-commercialization collaboration with GSK for anti-TIGIT monoclonal antibody EOS-448 (GSK''859); $625MM upfront payment in addition to $1.45B in potential milestones, …

FinanzNachrichten | August 12, 2021

Read More 'ITOS' Stories Here

ITOS Price Returns

1-mo 3.37%
3-mo 10.76%
6-mo -16.00%
1-year 19.80%
3-year N/A
5-year N/A
YTD -16.62%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9376 seconds.